Association Hospitaliere De Bruxelles Et De Schaerbeek Centre Hospitalier Universitaire Brugmann

Research site

Belgium Arthur Van Gehuchtenplein 4, 1020 Brussels, Belgium

9 trials recruiting
Arteriosclerosis · Acute hepatic failure · Alcohol abuse
Adults and children

About Specializations

Association Hospitaliere De Bruxelles Et De Schaerbeek Centre Hospitalier Universitaire Brugmann in Brussels, Belgium specialises in clinical trials of conditions such as Arteriosclerosis, Acute hepatic failure, Alcohol abuse, Asthma, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Clinical Trials

The Association Hospitaliere De Bruxelles Et De Schaerbeek Centre Hospitalier Universitaire Brugmann is advancing knowledge in Cardiovascular Diseases, targeting conditions such as Atherosclerotic Cardiovascular Disease and elevated lipoprotein(a). Ongoing studies evaluate whether novel agents like Lepodisiran can lower the risk of major adverse cardiac events.

Risk reduction in MACE-4 outcomes
Lipoprotein(a) lowering strategies
Cardiovascular outcome research

Researchers at the Brussels site are testing innovative therapies to improve heart health and reduce cardiovascular mortality.

Respiratory Clinical Trials

In the realm of Respiratory Tract Diseases, the department concentrates on severe allergic and eosinophilic asthma. Comparative trials assess the effectiveness of biologics such as omalizumab and mepolizumab in decreasing severe exacerbations.

Biologic therapy effectiveness
Predictive factors for treatment response
Reduction of asthma exacerbation rates

This research aims to personalize asthma management and enhance quality of life for patients in Brussels.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Arthur Van Gehuchtenplein 41020 BrusselsBelgium

Open in maps ↗

Recruiting now: 9 trials
Conditions studied: 21

More sites in Brussels Belgium

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

17 clinical trials

Non-small cell lung cancer stage IV

Recruiting

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Eikon Therapeutics Inc.

Contact Research Centre

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Eikon Therapeutics Inc.

Contact Research Centre

Breast cancer+1

Recruiting

Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Registered drug

Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:LY3437943 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Sickle cell disease

Recruiting

Study on Rilzabrutinib for Patients Aged 10-65 with Sickle Cell Disease

Investigational

Study on Rilzabrutinib for Patients Aged 10-65 with Sickle Cell Disease

Investigational

Belgium

Participants:0–17 years · 18–64 years
Substances:Rilzabrutinib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Alcohol abuse

Recruiting

Study on Psilocybin-Assisted Therapy for Patients with Severe Alcohol Use Disorder

Investigational

Study on Psilocybin-Assisted Therapy for Patients with Severe Alcohol Use Disorder

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol
Sponsor:Association Hospitaliere De Bruxelles Et De Schaerbeek Centre Hospitalier Universitaire Brugmann

Contact Research Centre

Orthopaedic procedure

Recruiting

Study on Methadone and Sufentanil for Pain Management After Orthopedic Surgery in Patients Without Locoregional Anesthesia

Registered drugNo placebo

Study on Methadone and Sufentanil for Pain Management After Orthopedic Surgery in Patients Without Locoregional Anesthesia

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Sufentanil
Sponsor:Association Hospitaliere De Bruxelles Et De Schaerbeek Centre Hospitalier Universitaire Brugmann

Contact Research Centre

Papilloma viral infection+1

Recruiting

Study on the Effectiveness of 2LPAPI with Interferon Alfa in Clearing Genital HPV Infections in Patients

Registered drug

Study on the Effectiveness of 2LPAPI with Interferon Alfa in Clearing Genital HPV Infections in Patients

Registered drug

Belgium

Participants:18–64 years
Substances:Ciclosporin A
Sponsor:Labo'Life Belgium

Contact Research Centre

HER2 positive breast cancer

Recruiting

Study Comparing Trastuzumab Deruxtecan with Standard Treatment for Patients with HER2-positive Breast Cancer

Registered drugNo placebo

Study Comparing Trastuzumab Deruxtecan with Standard Treatment for Patients with HER2-positive Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Aprepitant
Sponsor:Karolinska University Hospital

Contact Research Centre

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational

Belgium

Participants:18–64 years · 65+ years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Atorvastatin
Sponsor:Novartis Pharma AG

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Stemline Therapeutics Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites